312 related articles for article (PubMed ID: 26771843)
1. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.
Nunes-Xavier CE; Karlsen KF; Tekle C; Pedersen C; Øyjord T; Hongisto V; Nesland JM; Tan M; Sahlberg KK; Fodstad Ø
Oncotarget; 2016 Feb; 7(6):6891-901. PubMed ID: 26771843
[TBL] [Abstract][Full Text] [Related]
2. Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.
Flem-Karlsen K; Tekle C; Andersson Y; Flatmark K; Fodstad Ø; Nunes-Xavier CE
Pigment Cell Melanoma Res; 2017 Sep; 30(5):467-476. PubMed ID: 28513992
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
6. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
8. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
9. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
[TBL] [Abstract][Full Text] [Related]
10. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-199a Inhibits Cell Proliferation, Migration, and Invasion and Activates AKT/mTOR Signaling Pathway by Targeting B7-H3 in Cervical Cancer.
Yang X; Feng KX; Li H; Wang L; Xia H
Technol Cancer Res Treat; 2020; 19():1533033820942245. PubMed ID: 32856542
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts.
Euceda LR; Hill DK; Stokke E; Hatem R; El Botty R; Bièche I; Marangoni E; Bathen TF; Moestue SA
J Proteome Res; 2017 May; 16(5):1868-1879. PubMed ID: 28290700
[TBL] [Abstract][Full Text] [Related]
17. Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1/mTOR/VEGFA pathway.
Wu R; Zhang Y; Xu X; You Q; Yu C; Wang W; Mao Y
Cell Signal; 2023 Sep; 109():110737. PubMed ID: 37263461
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.
Jiang B; Liu F; Liu Z; Zhang T; Hua D
Tumour Biol; 2016 Jul; 37(7):9465-72. PubMed ID: 26787540
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
[TBL] [Abstract][Full Text] [Related]
20. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
Liu H; Tekle C; Chen YW; Kristian A; Zhao Y; Zhou M; Liu Z; Ding Y; Wang B; Mælandsmo GM; Nesland JM; Fodstad O; Tan M
Mol Cancer Ther; 2011 Jun; 10(6):960-71. PubMed ID: 21518725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]